Integrative study of lung cancer adeno-to-squamous transition in EGFR TKI resistance identifies RAPGEF3 as a therapeutic target
Authors:
Open Access
- 7 November 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in National Science Review
- Vol. 11 (12) , nwae392
Abstract
Although adeno-to-squamous transition (AST) has been observed in association with resistance to EGFR tyrosine kinase inhibitor (TKI) in clinic, its causality, molecular mechanism and overcoming strategies remain largely unclear. We here demonstrate that squamous transition occurs concomitantly with TKI resistance in PC9-derived xenograft tumors. Perturbation of squamous transition via DNp63 overexpression or knockdown leads to significant changes of TKI responses, indicative of a direct causal link between squamous transition and TKI resistance. Integrative RNA-seq, ATAC-seq analyses and functional studies reveal that FOXA1 plays an important role in maintaining adenomatous lineage and contributing to TKI sensitivity. FOXM1 overexpression together with FOXA1 knockout fully recapitulates squamous transition and TKI resistance in both PC9 xenografts and patient-derived xenograft (PDX) models. Importantly, pharmacological inhibition of RAPGEF3 combined with EGFR TKI efficiently overcomes TKI resistance, especially in RAPGEF3high PDXs. Our findings provide novel mechanistic insights into squamous transition and therapeutic strategy to overcome EGFR TKI resistance in lung cancer.Keywords
Funding Information
- National Key Research and Development Program of China (2022YFA1103900)
- Strategic Priority Research Program of the Chinese Academy of Sciences (XDB38040400)
- National Natural Science Foundation of China (82473426)
- Innovative Research Team of High-Level Local Universities in Shanghai (SSMU-ZLCX20180500)
- Science and Technology Commission of Shanghai Municipality (23JS1401300)
- JST Moonshot R&D (JPMJMS2021)
This publication has 62 references indexed in Scilit:
- C/EBPα and β couple interfollicular keratinocyte proliferation arrest to commitment and terminal differentiationNature Cell Biology, 2009
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- RETRACTED: Epac1‐induced cellular proliferation in prostate cancer cells is mediated by B‐Raf/ERK and mTOR signaling cascadesJournal of Cellular Biochemistry, 2009
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProceedings of the National Academy of Sciences of the United States of America, 2008
- Pioneer Factors, Genetic Competence, and Inductive Signaling: Programming Liver and Pancreas Progenitors from the EndodermCold Spring Harbor Symposia on Quantitative Biology, 2008
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- p63, Cell Adhesion and SurvivalCell Cycle, 2007
- Cell physiology of cAMP sensor EpacThe Journal of Physiology, 2006
- Perp Is a p63-Regulated Gene Essential for Epithelial IntegrityCell, 2005
- Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMPNature, 1998